LDL-Lowering Does Not Halt Progression of CKD: SHARPLDL-Lowering Does Not Halt Progression of CKD: SHARP
Lowering LDL cholesterol by 37.1 mg/dL with a combination of simvastatin and ezetimibe failed to halt the progression of kidney disease to end-stage renal disease in patients with chronic kidney disease. Heartwire
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Cardiology | Cholesterol | Chronic Kidney Disease | Heart | Simvastatin | Statin Therapy | Urology & Nephrology | Vytorin | Zetia | Zocor